Cargando…

Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!

Cachexia, and particularly the loss of metabolically active lean tissue, leads to increased morbidity and mortality in affected patients. An impairment of strength and functional status is usually associated with cachexia. A variety of anabolic and appetite-stimulating agents have been studied in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Thum, Thomas, Springer, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177042/
https://www.ncbi.nlm.nih.gov/pubmed/21966638
http://dx.doi.org/10.1007/s13539-011-0040-8
_version_ 1782212266446290944
author Thum, Thomas
Springer, Jochen
author_facet Thum, Thomas
Springer, Jochen
author_sort Thum, Thomas
collection PubMed
description Cachexia, and particularly the loss of metabolically active lean tissue, leads to increased morbidity and mortality in affected patients. An impairment of strength and functional status is usually associated with cachexia. A variety of anabolic and appetite-stimulating agents have been studied in patients with cachexia caused by various underlying diseases. Overall, these studies have demonstrated that treatment can increase body weight and/or lean body mass. However, these therapies may have severe side effects, particularly when utilizing testosterone and related anabolic steroids targeting the androgen receptor. These side effects include cardiovascular problems, prostate hyperplasia and cancer in men, as well as virilization in women.
format Online
Article
Text
id pubmed-3177042
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31770422011-09-30 Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?! Thum, Thomas Springer, Jochen J Cachexia Sarcopenia Muscle Editorial Cachexia, and particularly the loss of metabolically active lean tissue, leads to increased morbidity and mortality in affected patients. An impairment of strength and functional status is usually associated with cachexia. A variety of anabolic and appetite-stimulating agents have been studied in patients with cachexia caused by various underlying diseases. Overall, these studies have demonstrated that treatment can increase body weight and/or lean body mass. However, these therapies may have severe side effects, particularly when utilizing testosterone and related anabolic steroids targeting the androgen receptor. These side effects include cardiovascular problems, prostate hyperplasia and cancer in men, as well as virilization in women. Springer-Verlag 2011-09-21 2011-09 /pmc/articles/PMC3177042/ /pubmed/21966638 http://dx.doi.org/10.1007/s13539-011-0040-8 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Editorial
Thum, Thomas
Springer, Jochen
Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
title Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
title_full Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
title_fullStr Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
title_full_unstemmed Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
title_short Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
title_sort breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177042/
https://www.ncbi.nlm.nih.gov/pubmed/21966638
http://dx.doi.org/10.1007/s13539-011-0040-8
work_keys_str_mv AT thumthomas breakthroughincachexiatreatmentthroughanovelselectiveandrogenreceptormodulator
AT springerjochen breakthroughincachexiatreatmentthroughanovelselectiveandrogenreceptormodulator